KMA and Co.
  • Why
  • Who
  • What
  • Where
  • Case Studies
  • Thought Leadership
  • Blog
Select Page
In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

by Cassie Arnold | Feb 9, 2021 | Biotech Finance, COVID, Deal making, Investment

If you had an inkling that more money went to vaccine and diagnostic companies in 2020, you were right.  Diagnostics and vaccines have long been the red-headed stepchildren of life sciences investments. Detecting and treating life threatening diseases is the...

Recent Posts

  • Five Bits of Advice on MarCom Tactics
  • TL;DR*, Less is More, Short and Sweet
  • Digital Therapeutic Investment Soars — is there a bubble in our future?
  • Digital Therapeutics is Primed for a Return to the Roaring 20’s
  • In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

Archives

  • March 2022
  • August 2021
  • July 2021
  • April 2021
  • February 2021
  • January 2021
  • November 2020
  • August 2020
  • July 2020
  • April 2020
  • February 2020
  • November 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • April 2019
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • March 2018
  • February 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • September 2016
  • August 2016
  • April 2016
  • March 2016
  • February 2016
  • December 2015
  • October 2015
  • June 2015
  • April 2015
  • March 2015
  • February 2015
  • November 2014
  • October 2014
  • August 2014
  • June 2014

Categories

  • 21st Century Culture
  • Advertising
  • Biotech Finance
  • Branding
  • Communications
  • COVID
  • Deal making
  • Digital Health
  • Digital Therapeutic
  • Digital Therapeutics
  • Gender at Work
  • Investment
  • Modern Work
  • Persuasion
  • Sales
  • Uncategorized
  • Venture capital
  • Twitter
  • RSS
© 2021 KMA & Company